Loading
TG4070 is an experimental individualised neoantigen therapeutic vaccine from Transgene, in phase 1 trials for non-small cell lung cancer.
TG4070 is an individualised neoantigen therapeutic vaccine (myvac platform) from Transgene. Transgene's second individualised neoantigen therapeutic vaccine from the myvac platform, given with nivolumab after surgery. Its furthest stage is phase 1, for non-small cell lung cancer (resected, adjuvant). No clinical trial naming it is registered on ClinicalTrials.gov. Transgene: phase 1 in resected NSCLC after neoadjuvant nivolumab plus chemotherapy. No ClinicalTrials.gov record found for TG4070 (query.intr and query.term searched). It has not been shown to work in people.
Transgene's second individualised neoantigen therapeutic vaccine from the myvac platform, given with nivolumab after surgery.
1.TG4070 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"TG4070" OR ABSTRACT:"TG4070") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TG4070, not a curated reading list.
Shares Transgene and the tag pipeline.
Shares Transgene and the tag pipeline.
Shares Transgene and the tag pipeline.
Shares Transgene and the tag pipeline.
Shares Transgene and the tag pipeline.
Shares Transgene and the tag pipeline.
Shares Transgene and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/